Morphic Holding (DB:31Y) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

31Y Overzicht aandelen

A biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.

Over het bedrijf

31Y fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 81.51% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 6.4% per jaar dalen.

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

Morphic Holding, Inc. Concurrenten

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€863.4m

Heidelberg Pharma

XTRA:HPHA

€116.5m

Medigene

XTRA:MDG1

€24.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Morphic Holding
Historische aandelenkoersen
Huidige aandelenkoers	US$50.00
52 Week Hoogtepunt	US$52.50
52 Week Laag	US$18.50
Bèta	1.49
11 maand verandering	0.81%
3 maanden verandering	71.23%
1 Jaar Verandering	8.70%
33 jaar verandering	5.49%
5 jaar verandering	156.15%
Verandering sinds IPO	145.27%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	31Y	DE Biotechs	DE Markt
7D	-1.0%	-3.1%	-1.0%
1Y	8.7%	-15.2%	16.1%

Rendement versus industrie: 31Y overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -15.2 % opleverde.

Rendement versus markt: 31Y overtrof de German markt, die het afgelopen jaar een rendement opleverde van 16.1 %.

Prijsvolatiliteit

Is 31Y's price volatile compared to industry and market?
31Y volatility
31Y Average Weekly Movement	22.9%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

Stabiele aandelenkoers: De aandelenkoers van 31Y is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van 31Y is het afgelopen jaar gestegen van 15% naar 23%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	128	Praveen Tipirneni	www.morphictx.com

Morphic Holding, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Morphic Holding zich tot de beurswaarde?
31Y fundamentele statistieken
Marktkapitalisatie	€2.60b
Inkomsten(TTM)	-€163.57m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-15.9x

Koers/Winstverhouding

Is 31Y overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
31Y resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$165.93m
Brutowinst	-US$165.93m
Overige uitgaven	US$13.90m
Inkomsten	-US$179.83m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-3.58
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 31Y op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

31Y Overzicht aandelen

Beloningen

Risicoanalyse

Morphic Holding, Inc. Concurrenten

XTRA:BIO3

€1.3b

XTRA:FYB

€863.4m

XTRA:HPHA

€116.5m

XTRA:MDG1

€24.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

New major risk - Share price stability

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Full year 2023 earnings released: US$3.59 loss per share (vs US$1.55 loss in FY 2022)

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

New major risk - Share price stability

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Full year 2023 earnings released: US$3.59 loss per share (vs US$1.55 loss in FY 2022)

Insufficient new directors

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

First quarter 2023 earnings released: US$0.90 loss per share (vs US$0.85 loss in 1Q 2022)

Full year 2022 earnings released: US$1.55 loss per share (vs US$2.67 loss in FY 2021)

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

Third quarter 2022 earnings released: US$0.78 loss per share (vs US$0.69 loss in 3Q 2021)

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Second quarter 2022 earnings released: EPS: US$0.70 (vs US$0.77 loss in 2Q 2021)

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

First quarter 2022 earnings released: US$0.85 loss per share (vs US$0.64 loss in 1Q 2021)

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Morphic Therapeutic Announces Management Appointments

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

Founder recently bought €3.6m worth of stock

Second quarter 2021 earnings released: US$0.77 loss per share (vs US$0.52 loss in 2Q 2020)

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Index

Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 At ECCO'21 Virtual Congress

Founder recently bought €8.7m worth of stock

Independent Director has left the company

First quarter 2021 earnings released: US$0.64 loss per share (vs US$0.56 loss in 1Q 2020)

Morphic Announces Clinical Results Update

Independent Director recently bought €59k worth of stock

Full year 2020 earnings released: US$1.47 loss per share (vs US$2.69 loss in FY 2019)

Revenue misses expectations

Morphic Holding, Inc. Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057

New 90-day high: €68.50

New 90-day high: €28.20

Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program

New 90-day high: €27.20

Morphic Holding, Inc. Appoints Martin Edwards to Serve on the Board as A Class II Director

New 90-day high: €25.60

Third quarter 2020 earnings released: EPS US$0.17

Revenue beats expectations

Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020

Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000 Value Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Morphic Holding, Inc. Samenvatting

0.0x

-15.9x

Inkomsten en omzet